Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Astellas Pharma ( (JP:4503) ) just unveiled an announcement.
Astellas Pharma has revised its financial forecasts for fiscal year 2024, driven by the expansion of XTANDI™ sales in the U.S. and favorable foreign exchange impacts that are anticipated to boost revenue and profit. However, the company will incur significant impairment losses due to the withdrawal of a marketing application for IZERVAY™ in Europe, updates to its gene therapy program, and the discontinuation of certain projects, leading to a revised financial outlook with increased revenue but decreased profit figures on a full basis.
More about Astellas Pharma
Astellas Pharma Inc. is a Japanese pharmaceutical company that focuses on the development and sales of innovative medicines, primarily in the areas of oncology, urology, immunology, nephrology, and neuroscience. The company is known for its product XTANDI™, used in the treatment of prostate cancer, and is strategically expanding its market presence in the United States.
YTD Price Performance: -2.54%
Average Trading Volume: 4,705
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $17.21B
For an in-depth examination of 4503 stock, go to TipRanks’ Stock Analysis page.